Anti- Müllarian hormone (AMH) as an indicator of ovarian reserve in acne patients treated with isotretinoin

Abstract

Background: Isotretinoin suppresses sebum development by inducing sebocyte apoptosis, which is induced by the expression of tumour necrosis factor-related apoptosis-inducing ligand, insulin-like growth factor binding protein-3, and neutrophil gelatinase-associated lipocalin, which is induced by isotretinoin. While apoptosis could play a role in the drug's key mechanism of action, it may also be to blame for the majority of isotretinoin's side effects, including ovarian reserve impairment. The aim of this study was to see if AMH could be used as a measure of ovarian reserve in isotretinoin-treated acne patients. The participants in this study were 66 female patients in their reproductive years who had various degrees of acne. All of the patients were chosen from the Dermatology and Andrology Department of Benha University Hospitals' outpatient clinic. The research lasted anywhere from 6 to 12 months. The average age of the patients in this study was 25 years, with a standard deviation of 6 years. There was no substantial difference in AMH before and after Isotretinoin therapy. The percentage change in AMH after treatment had no important relationship with the patients' age, Isotretinoin dosage, or treatment period. Isotretinoin has a negative impact on the ovaries, according to the findings. More research is required to gain a better understanding of this subject and to see if the effects are permanent.